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Purpose: Forkhead box p3 (Foxp3) positive T regulatory
cells (Tregs) have a functionally immunosuppressive property
that prevents effector cells from acting against self in auto-
immune diseases or a tumor. It is known that Tregs may be
highly relevant in cancer progression. Dendritic cells (DCs)
induce cutaneous immune response, however several studies
have suggested that DCs are involved in immunosuppression.
The aim of this study is to evaluate the prevalence of Tregs
and DCs infiltration in cutaneous premalignant and malignant
squamous lesions. Materials and Methods: We evaluated Tregs
and DCs in skin tissue samples obtained from 83 patients with
actinic keratosis, Bowen's disease or squamous cell carcinoma
by immunohistochemistry. Results: The prevalence of Tregs
and DCs was significantly higher in squamous cell carcinoma
and Bowen's disease than in actinic keratosis. In addition, the
number of DCs was closely correlated with the prevalence of
Tregs, and DCs were also located in direct proximity to Tregs.
Conclusion: Tregs is related to cutaneous squamous tumor
progression.
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INTRODUCTION
It is known that actinic keratosis and Bowen's
disease, both intraepidermal skin tumors, have a
potential progression to squamous cell carcinoma.
Skin cancer constitutes one of the most frequent
types of malignancies in humans with rapidly
increasing worldwide incidences. Ultraviolet radia-
tion (UVR) is an essential risk factor for the de-
velopment of premalignant as well as malignant
skin lesions.
1 UVR can function as a complete
carcinogen by inducing DNA mutations and by
suppressing protective cellular antitumoral immune
responses.
2 Recent data showed that UVB-dendritic
cell (DC) induces regulatory CD4
+CD25
+ cytotoxic
T-lymphocyte-associated antigen-4 (CTLA-4
+) T
cells.
3
Dendritic cells (DCs) induce cutaneous immune
response, however, several studies have suggested
that DCs are involved in immunosuppression.
4,5
DC-derived immunosuppression can result from
antigen presentation by immature DCs that lack
sufficient accessory molecules. In addition, im-
mature DCs can differentiate into tolerogenic DCs
under the influence of IL-10, TNF and T regula ɑ -
tory cells (Tregs).
5 Recently, epidermal expression
of CD254 (receptor activator of NF-kappaB ligand,
RANKL) has been shown to connect UVR with
immunosuppression and tolerogenic phenotype in
DCs and expansion of Tregs.
6,7 Tregs are thought
to be functionally unique population of T cells,
and function to maintain immune homeostasis.
8-10
Tregs have a functionally immunosuppressive
property that inhibits effector cells to act against
self in autoimmune diseases or a tumor. Foxp3, a
member of the forkhead or winged helix family of
transcription factors, is thought to be most reliable
marker for Tregs.
11,12 Foxp3 protein is responsible
for scurfy mouse and human disorder of immune
dysregulation, polyendocrinopathy, enteropathy,
and X-linked inheritance, both of which are
characterized by lack of CD4
+CD25
+ Tregs.
13,14 Tregs
may be highly relevant in cancer progression.
Elevated numbers of Tregs have been found in
cancer patients, and it has been shown that the
elimination of Tregs may be used to enhance anti-
tumoral immune responses.
15-20 There is, however,
Prevalence of Foxp3 Positive T Regulatory Cells is Increased
during Progression of Cutaneous Squamous Tumors
Tae Jung Jang
Department of Pathology, Dongguk University College of Medicine, Kyongju, Korea.
Received March 17, 2008
Accepted June 30, 2008 
Reprint address: requests to Dr. Tae Jung Jang, Department of
Pathology, Dongguk University College of Medicine, 707 Sukjang-
dong, Kyongju, Kyongbuk 780-714, Korea. Fax: 82-54-770-2431,
Tel: 82-54-770-2410, Email: taejung@mail.dongguk.ac.krT Regulatory Cells in Skin Squamous Tumors
Yonsei Med J Vol. 49, No. 6, 2008
limited information describing the prevalence of
Tregs infiltration in premalignant and malignant
skin lesions. The aim of this study was to evaluate
the prevalence of Tregs and DCs infiltration in
cutaneous premalignant and malignant squamous
lesions by immunohis-tchemistry.
MATERIALS AND METHODS
Patients
Eighty-three patients with actinic keratosis,
Bowen's disease or squamous cell carcinoma
treated at Dongguk University Kyongju Hospital
were enrolled in this study. The characteristics of
the study subjects are summarized in Table 1.
None of the patients received radiotherapy or
chemotherapy before diagnosis.
Immunohistochemistry
Skin sections of 4 m thickness were made and μ
spread on poly-L-lysine coated slides. Paraffin
sections were immersed in three changes of xylene
and hydrated using a graded series of alcohol.
Antigen retrieval was performed routinely by
immersing the sections in sodium citrate buffer
(pH 6.0 for Ki67) or Tris-EDTA buffer (pH 6.0 for
Foxp3) in a pressure cooker by autoclaving for 15
minutes. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide for 15 minutes
and then incubated with primary antibody for 2
hours at room temperature. Primary antibodies
were rabbit polyclonal anti-S100 (DakoCytomation,
Carpinteria, CA, USA, dilution 1 : 500), mouse
monoclonal anti-Ki67 antibody (Zymed Laborato-
ries, South San Franciso, CA, USA, dilution 1 :
200) and mouse monoclonal anti-Foxp3 antibody
(Abcam, Cambridge, UK, dilution 1 : 100). Staining
was done with a Dako EnVision kit labeled with
peroxidase (DakoCytomation) and developed
with 3, 3'-diaminobenzidine tetrahydrochloride
(Zymed) as a chromogen. Sections were counter-
stained for 3 minutes with Meyers hematoxylin
and then mounted. As a negative control, rabbit
and mouse IgG isotypes were used instead of
primary antibody. In addition, double-staining
immunohistochemistry was performed in human
tonsil with anti-Foxp3 antibody and anti-CD4 anti-
body (DakoCytomation) to confirm that Foxp3(+)
cells were really CD4(+). Second staining was
performed with a LSAB+kit labeled with alkaline
phosphatase (DakoCytomation) and developed
with Permanent Red (DakoCytomation) as a chro-
mogen. The Foxp3 labeling index (LI) was calculated
by counting positive cells in 500 lymphocytes
throughout entire area of tumor stroma at a
magnification of × 400. In the case of Ki67 LI, at
least 500 malignant squamous cells were counted
throughout entire area of tumor at a magnification
of × 400. The number of S100 positive DCs in five
randomly selected tumor stroma areas was
analyzed at a magnification of × 400 and averaged.
To examine the relationship of topographic dis-
tribution between S100 positive DCs and Tregs,
figures of immunohistochemical staining for S100
and Foxp3 were merged on the Adobe Photoshop
9.0.
Statistical analysis
Pearson correlation and one-way ANOVA were
used. Statistical significance was assumed if a p
value was less than 0.05. Data were expressed as
mean ± standard deviation (SD).
RESULTS
To confirm that Foxp3(+) cells were really CD4
(+), double staining immunohistochemistry was
Table 1. The Characteristics of Study Subjects
Diagnosis Subjects (n) Age (mean ± SD) Gender (male : female)
Actinic keratosis 32 72 ± 9 11 : 21
Bowen's disease 24 63 ± 14 9 : 15
Squamous cell carcinoma 27 74 ± 11 7 : 20Tae Jung Jang
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done in human tonsil. Most of Foxp3(+) and CD4
(+) lymphocytes were present in paracortical area.
Some of CD4(+) lymphocytes showed positive
signal for Foxp3 (Fig. 1A). Tregs stayed in close
proximity to S100(+) DCs (Fig. 1B). Foxp3 LI was
0.28 ± 0.11, 0.27 ± 0.13 and 0.19 ± 0.08 in squamous
cell carcinoma, Bowen's disease and actinic kerato-
sis, respectively. As shown in Fig. 2. Foxp3 LI was
Fig. 1. Double-staining immunohistochemistry with anti-Foxp3 antibody (pink) and a anti-CD4 antibody (brown) in human
tonsil (A), and combination of immunohistochemical staining for S100 and Foxp3 (B). (A) Some of CD4(+) lymphocytes
show positive signal for Foxp3 (arrow). (B) Tregs (arrow) stay in close proximity to S100(+) DC (arrowhead).
Fig. 2. Foxp3 LI (A) and representative pictures of immunohistochemical staining for Foxp3 (B, C, and D) in actinic keratosis
(AK, B), Bowen's disease (BD, C), and squamous cell carcinoma (SCC, D). Foxp3 LI was significantly higher in SCC and
BD than in AK (p < 0.05).
A B
A B
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significantly higher in squamous cell carcinoma
and Bowen's disease than in actinic keratosis (p <
0.05). In each disease, there was no significant dif-
ference in Foxp3 LI between age and gender (data
not shown). In squamous cell carcinoma, Foxp3 LI
was 0.28 ± 0.13 and 0.30 ± 0.07 in well differentia-
tion tumors (N = 13) and moderate to poor tumors
(N = 14), respectively, and insignificantly related to
Ki67 LI. There was also no significant difference
in Foxp3 LI between tumor differentiation and
Ki67 LI (p> 0.05). The number of S100 positive DCs
was 26.45 ± 16.02, 20.21 ± 13.94 and 12.47 ± 7.03 in
squamous cell carcinoma, Bowen's disease and
actinic keratosis, respectively, As shown in Fig. 3,
total DCs infiltration was significantly higher in
squamous cell carcinoma and Bowen's disease than
in actinic keratosis (p < 0.05). In each disease, there
was no significant difference in the number of DCs
between age and gender (data not shown). In
squamous cell carcinoma, the number of DCs was
22.39 ± 11.76 and 29.60 ± 17.35 in well differentia-
tion tumors (N= 13) and moderate to poor tumors
(N = 14), respectively, and insignificantly related to
Ki67 LI. There was also no significant difference
in the number of DCs between tumor differentia-
tion and Ki67 LI. As shown in Fig. 4, the number
of DCs was closely correlated with Foxp3 LI (r =
Fig. 3. The number of DCs (A) and representative pictures of immunohistochemical staining for S100 in AK (B), BD (C)
and SCC (D). The number of DCs was significantly higher in SCC and BD than in AK (p < 0.05). DCs, dendritic cells; AK,
actinic keratosis; BD, Bowen's disease; SCC, squamous cell carcinoma.
Fig. 4. Correlation between Foxp3 LI and the number of
dendritic cells. The number of DCs was closely correlated
with Foxp3 LI (r = 0.378, p < 0.05).
A B
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0.378, p < 0.05).
DISCUSSION
For the first time, this study performed in situ
analysis of Tregs in cutaneous premalignant and
malignant squamous lesions, and showed that the
population of Tregs and DCs were increased in
Bowen's disease and cutaneous squamous cell
carcinoma compared to actinic keratosis. In addi-
tion, Tregs infiltration was closely related with the
number of infiltrating DCs, and Tregs were also
located in direct proximity to DCs.
Naturally arising CD4
+CD25
+ Tregs characteris-
tically express CD25, CTLA-4, glucocorticoid-
induced tumor necrosis factor receptor family
related gene (GITR), surface transforming growth
factor- (TGF- ), and Foxp3. CD25 is a critical β β
molecule for proliferation and survival of CD4
+
CD25
+ Tregs.
21 However, CD25 is not a suitable
marker to define Tregs because activated T cells
generally express CD25. Compelling studies have
revealed that CTLA-4 and TGF- play roles in the β
suppressive activity of CD4
+CD25
+ Tregs against
CD4
+ or CD8+ T cells, although they are not ex-
pressed exclusively in Tregs. Experiments with
Foxp3-overexpressing transgenic or Foxp3 gene-
depleted mice and other studies have shown that
Foxp3 is a master control gene for the develop-
ment and function of natural CD4
+CD25
+ Tregs.
21-24
Thus, Foxp3 is thought to be a suitable single
marker for detecting CD4
+CD25
+ Tregs.
In murine models, Tregs inhibit the antitumor
immune response mediated by CD4
+CD25
- T cells
and CD8
+ cytotoxic T cells.
25-28 Population of Tregs
in tumor infiltrating lymphocytes are significantly
larger than in normal tissue in several malign-
ancies.
16-20 Moreover, Tregs infiltration is correlated
with tumor progression in pancreatic ductal
adenocarcinoma and gastric cancer.
19,20 In this
study, the population of Tregs were also increased
in Bowen's disease and cutaneous squamous cell
carcinoma compared to actinic keratosis. Thus,
Tregs may highly be relevant in several human
cancer progression. Since high Tregs infiltration
reduces the anti-tumor immunity, Tregs infiltration
has been suggested to be poor prognostic factor
in several malignancies.
17,20,29-31 On the contrary,
recent studies showed that clinical outcome is not
dependent on Tregs infiltration in renal cell cancer
and colon cancer.
32,33 Moreover, there is close
correlation between Tregs infiltration and good
survival in follicular lymphoma.
34 The present
study revealed that Tregs infiltration was not
correlated with Ki67 LI in squamous cell car-
cinoma. Overall, it remains controversial as to
whether Tregs infiltration is related to clinical
behaviour.
The present study revealed that DCs infiltration
was significantly in Bowen's disease and squamous
cell carcinoma compared to actinic kertatosis.
Moreover, the number of DCs was strongly related
to Tregs infiltration, and DC stayed in close proxi-
mity to Tregs. A recent report showed that S100
positive DCs infiltration were correlated with Tregs
infiltration in colon cancers, and also demonstrated
that S100 positive DCs was primarily immature
DCs.
35 The function of DC effector strictly depend
on both maturation stage and on environmental,
anti-inflammatory or pro-inflammatory signals.
36
Mature DCs have been regarded as inducers of
T-cell immunity and vigorous T-cell proliferative
responses, whereas immature DCs have been con-
sidered as inducers of T reg cells with inherent low
ability to proliferate in response to mitogens or
antigens.
36 It is known that RANK and RANKL are
key regulators of bone remodeling, mammary
gland formation, lymph node development and
T-cell/DC communication.
6 RANKL overexpression
in keratinocytes resulted in functional alterations
of epidermal DCs and systemic increases of Tregs.
6
RANK-RANKL signaling between RANK-expres-
sing epidermal DCs and RANKL-overexpressing
keratinocytes in K14-RANKL transgenic epidermis
resulted in the up-regulation of DEC205 on
epidermal DCs, a marker that has previously been
associated with the induction of a tolerogenic
phenotype in DCs.
7 Moreover, DCs co-cultured
with Tregs may also down-regulate the expression
of costimulatory molecules, release large quantities
of IL-10 and become unable to properly trigger
T-cell activation.
37,38 Recent studies also demon-
strated direct contact of Treg with DC in vivo.
39-41
Taken together, Tregs may act by directly targeting
effector T cells, by competing with pathogenic T
cells for access to antigen presenting cells (APCs)
or by directly targeting APCs.T Regulatory Cells in Skin Squamous Tumors
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In conclusion, this study shows that Tregs are
related to cutaneous squamous tumor progres-
sion.
REFERENCES
1. Urbach F. Ultraviolet radiation and skin cancer of
humans. J Photochem Photobiol B 1997;40:3-7.
2. Beissert S, Loser K. Molecular and cellular mechanisms
of photocarcinogenesis. Photochem Photobiol 2008;84:
29-34.
3. Simon JC, Hara H, Denfeld RW, Martin S. UVB-irradi-
ated dendritic cells induce nonproliferating, regulatory
type T cells. Skin Pharmacol Appl Skin Physiol
2002;15:330-4.
4. Lutz MB, Schuler G. Immature, semi-mature and fully
mature dendritic cells: which signals induce tolerance
or immunity? Trends Immunol 2002;23:445-9.
5. Enk AH. Dendritic cells in tolerance induction. Immunol
Lett 2005;99:8-11.
6. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe
S, et al. Epidermal RANKL controls regulatory T-cell
numbers via activation of dendritic cells. Nat Med
2006;12:1372-9.
7. Mahnke K, Qian Y, Knop J, Enk AH. Induction of
CD4
+/CD25
+ regulatory T cells by targeting of antigens
to immature dendritic cells. Blood 2003;101:4862-9.
8. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop
J, Enk AH. Identification and functional characteriza-
tion of human CD4(+)CD25(+) T cells with regulatory
properties isolated from peripheral blood. J Exp Med
2001;193:1285-94.
9. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi
G, Edwards AD, et al. Human CD4(+)CD25(+) cells: a
naturally occurring population of regulatory T cells.
Blood 2001;98:2736-44.
10. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M.
Immunologic self-tolerance maintained by activated T
cells expressing IL-2 receptor alpha-chains (CD25).
Breakdown of a single mechanism of self-tolerance
causes various autoimmune diseases. J Immunol 1995;
155:1151-64.
11. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs
the development and function of CD4
+CD25
+ regulatory
T cells. Nat Immunol 2003;4:330-6.
12. Hori S, Nomura T, Sakaguchi S. Control of regulatory
T cell development by the transcription factor Foxp3.
Science 2003;299:1057-61.
13. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark
LB, Yasayko SA, et al. Disruption of a new forkhead/
winged-helix protein, scurfin, results in the fatal lym-
phoproliferative disorder of the scurfy mouse. Nat
Genet 2001;27:68-73.
14. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgar-
opoulos C, Helms C, et al. JM2, encoding a fork
head-related protein, is mutated in X-linked autoim-
munity-allergic disregulation syndrome. J Clin Invest
2000;106:R75-81.
15. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tu-
mor immunity by removing CD25
+CD4
+ T cells: a com-
mon basis between tumor immunity and autoim-
munity. J Immunol 1999;163:5211-8.
16. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H,
Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in
tumors from patients with early-stage non-small cell
lung cancer and late-stage ovarian cancer. Cancer Res
2001;61:4766-72.
17. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann
V, Doherty G, et al. Prevalence of regulatory T cells is
increased in peripheral blood and tumor microenviron-
ment of patients with pancreas or breast adenocar-
cinoma. J Immunol 2002;169:2756-61.
18. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP,
Greten TF, Korangy F. Increased populations of regu-
latory T cells in peripheral blood of patients with hep-
atocellular carcinoma. Cancer Res 2005;65:2457-64.
19. Mizukami Y, Kono K, Kawaguchi Y, Akaike H,
Kamimura K, Sugai H, et al. Localisation pattern of
Foxp3+ regulatory T cells is associated with clinical be-
haviour in gastric cancer. Br J Cancer 2008;98:148-53.
20. Hiraoka N, Onozato K, Kosuge T, Hirohashi S.
Prevalence of Foxp3+ regulatory T cells increases during
the progression of pancreatic ductal adenocarcinoma
and its premalignant lesions. Clin Cancer Res 2006;12:
5423-34.
21. Sakaguchi S. Naturally arising Foxp3-expressing
CD25
+CD4
+ regulatory T cells in immunological toler-
ance to self and non-self. Nat Immunol 2005;6:345-52.
22. von Boehmer H. Mechanisms of suppression by sup-
pressor T cells. Nat Immunol 2005;6:338-44.
23. Fontenot JD, Rudensky AY. A well adapted regulatory
contrivance: regulatory T cell development and the
forkhead family transcription factor Foxp3. Nat
Immunol 2005;6:331-7.
24. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL,
Farr AG, Rudensky AY. Regulatory T cell lineage speci-
fication by the forkhead transcription factor Foxp3.
Immunity 2005;22:329-41.
25. Chen ML, Pittet MJ, Gorelik L, Flavell RA. Weissleder
R, von Boehmer H, et al. Regulatory T cells suppress
tumor-specific CD8 T cell cytotoxicity through TGF-ba-
ta signals in vivo. Proc Natl Acad Sci U S A 2005;102:
419-24.
26. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tu-
mor immunity by removing CD25
+CD4
+ T cells: a com-
mon basis between tumor immunity and autoim-
munity. J Immunol 1999;163:5211-8.
27. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T,
Nakayama E. Tumor rejection by in vivo administration
of anti-CD25 (interleukin-2 receptor ) monoclonal anti ɑ -
body. Cancer Res 1999;59:3128-33.
28. Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K,
Wang L, et al. Accelerated chemically induced tumor
development mediated by CD4
+CD25
+ regulatory TTae Jung Jang
Yonsei Med J Vol. 49, No. 6, 2008
cells in wild-type hosts. Proc Natl Acad Sci U S A 2005;
102:9253-7.
29. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P,
Mottram P, et al. Specific recruitment of regulatory T
cells in ovarian carcinoma fosters immune privilege
and predicts reduced survival. Nat Med 2004;10:942-9.
30. Alvaro T, Lejeune M, Salvado MT, Bosch R, García JF,
Jaén J, et al. Outcome in Hodgkin's lymphoma can be
predicted from the presence of accompanying cytotoxic
and regulatory T cells. Clin Cancer Res 2005;11:1467-73.
31. Wolf D, Hochegger K, Wolf AM, Rumpold HF, Gastl
G, Tilg H, et al. The expression of the regulatory T
cell-specific forkhead box transcription factor FoxP3 is
associated with poor prognosis in ovarian cancer. Clin
Cancer Res 2005;11:8326-31.
32. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M,
Kuntz SM, Krambeck AE, et al. Tumor infiltrating
Foxp3
-CD4
+CD25
+ T cells predict poor survival in renal
cell carcinoma. Clin Cancer Res 2007;13:2075-81.
33. Loddenkemper C, Schernus M, Noutsias M, Stein H,
Thiel E, Nagorsen D. In situ anlaysis of FOXP3+ egula-
tory T cells in human colorectal cancer. J Transl Med
2006;4:52.
34. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L,
Martinez A, Roncador G, et al. High numbers of tu-
mor-infiltrating FOXP3-positive regulatory T cells are
associated with improved overall survival in follicular
lymphoma. Blood 2006;108:2957-64.
35. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E,
Loddenkemper C. Tumor-infiltrating macrophages and
dendritic cells in human colorectal cancer: relation to
local regulatory T cells, systemic T-cell response against
tumor-associated antigens and survival. J Transl Med
2007;5:62.
36. Rutella S, Lemoli RM. Regulatory T cells and tolero-
genic dendritic cells: from basic biology to clinical
applications. Immunol Lett 2004;94:11-26.
37. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine
MD, Kaveri SV. Cutting edge human CD4
+CD25
+ T cells
restrain the maturation and antigen-presenting function
of dendritic cells. J Immunol 2004;172:4676-80.
38. Cederbom L, Hall H, Ivars F. CD4
+CD25
+ regulatory T
cells down-regulate co-stimulatory molecules on anti-
gen-presenting cells. Eur J Immunol 2000;30:1538-43.
39. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC,
Maraver A, et al. Regulatory T cells inhibit stable con-
tacts between CD4
+ T cells and dendritic cells in vivo.
J Exp Med 2006;203:505-11.
40. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P,
et al. Visualizing regulatory T cell control of autoim-
mune responses in nonobese diabetic mice. Nat Immunol
2006;7:83-92.
41. Mahnke K, Ring S, Johnson TS, Schallenberg S,
Schönfeld K, Storn V, et al. Induction of immuno-
suppressive functions of dendritic cells in vivo by CD4
+
CD25
+ regulatory T cells: role of B7-H3 expression and
antigen presentation. Eur J Immunol 2007;37:2117-26.